LAM-003 activity against TKI-resistant primary AML blasts harboring FLT3-ITD. (A) Three primary AML samples all harboring FLT3-ITD were treated with LAM-003 for 72 hours before Annexin V/7-AAD staining was assessed on CD45⁺/CD34⁺ blasts. (B) Primary AML blasts from a TKI-relapsed patient were treated with gilteritinib (left) or LAM-003 (right) for 72 hours before cell viability was assessed by using 7-AAD/Annexin V staining as in panel A. (C) Normalized isobologram at the EC₇₅ of 2 primary AML samples, both harboring FLT3-ITD, with the combination of LAM-003 and venetoclax for 72 hours before being assayed for Annexin V/7-AAD staining as in panel A.